Vnitřní lékařství 5/2021

PŘEHLEDOVÉ ČLÁNKY Preleukemické fúzne gény typické pre akútnu myeloidnú leukémiu E12 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék 2021; 67(e5): e9–e12 / www.casopisvnitrnilekarstvi.cz 8. Kosik P, Durdik M, Skorvaga M, Klimova D. Induction of AML Preleukemic Fusion Genes in HSPCs and DNA Damage Response in Preleukemic Fusion Gene Positive Samples. An­ tioxidants 2021; 10(3), 481. 9. Laguna‑Olmos M et al. Leucemia mieloide aguda y pre‑eclampsia coexistente. Algu­ nas dificultades diagnósticas. A propósito de un caso. Revista chilena de obstetricia y gi­ necologia 2020; 85(2): 155–161. 10. https://ghr.nlm.nih.gov/gene/AML1 [cit. 2021-02-18] 11. Krejci O, Wunderlich M, Geiger H. p53 signaling in response to increased DNA da­ mage sensitizes AML1-ETO cells to stress‑induced death. Am. J. Hematol 2008; 111(4), 2190–2199. 12. Oo Z M, Illendula A, Grembecka J. A tool compound targeting the core binding factor Runt domain to disrupt binding to CBFβ in leukemic cells. Leukemia & lymphoma 2018; 59(9), 2188–2200. 13. Zahedipour F, Ranjbaran R, Behzad A et al. Development of Flow Cytometry‑Fluorescent In Situ Hybridization (Flow‑FISH) Method for Detection of PML/RARa Chromosomal Tran­ slocation in Acute Promyelocytic Leukemia Cell Line. Avicenna J. Med. Biotechnol 2017; 9(2): 104–108. 14. Lallemand‑Breitenbach, V. PML nuclear bodies. Cold Spring Harb Perspect Biol 2010; 2(5). 15. Matt S, Hofmann T. G. Crosstalk between p53 modifiers at PML bodies. Molecular & ce­ llular oncology 2018; 5(3). 16. Wang, G, Tian Y, Hu Q. PML/RARa blocks the differentiation and promotes the prolife­ ration of acute promyelocytic leukemia through activating MYB expression by transcrip­ tional and epigenetic regulation mechanisms. J. Cell. Biochem 2019; 120(2): 1210–1220. 17. Zhu H H, Yang M C, Wang F. Identification of a novel NUP98–RARA fusion transcript as the 14 th variant of acute promyelocytic leukemia. Am. J. Hematol 2020; 95(7): E184–E186. 18. Testi A M, Biondi A, Coco F L et al. Protocol for the treatment of newly diagnosed acu­ te promyelocytic leukemia (APL) in children. Blood 2005; 106(2), 447–453. 19. Soignet S L, Maslak P, Wang Z et al. Complete Remission After Treatment of Acute Pro­ myelocytic. NEJM 1998; 339: 1341–1348. 20. Burnett A K, Russell N H, Hills R K. Myeloid Leukaemia Working Group. Arsenic trioxide and all‑trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. The Lancet Oncology 2015; 16(13): 1295–1305. 21. Platzbecker U, Avvisati G, Cicconi L. Improved outcomes with retinoic acid and arse­ nic trioxide compared with retinoic acid and chemotherapy in non‑high‑risk acute pro­ myelocytic leukemia: final results of the randomized Italian‑German APL0406 trial. Am. J. Clin. Oncol 2017. 22. Bernard O, Berger R. Molecular basis of 11q23 rearrangements in hematopoietic ma­ lignant proliferations. Genes Chromosomes Cancer 1995;13: 75–85. 23. Balgobind B V, Raimondi S C, Harbott J et al Novel prognostic subgroups in childhood 11q23/MLL‑rearranged acute myeloid leukemia: results of an international retrospective study. Blood 2009; 114(12), 2489–2496. 24. Kuntimaddi A, Achille N J, Thorpe J. Degree of recruitment of DOT1L to MLL‑AF9 de­ fines level of H3K79 di- and tri‑methylation on target genes and transformation poten­ tial. Cell Rep 2015; 11: 808–820. 25. Rowley JD. The critical role of chromosome translocations in human leukemias. Annu. Rev. Genet 1998; 32(1), 495–519. 26. Tonks A, Tonks A J, Pearn L et al. Expression of AML1-ETO in human myelomonocytic cells selectively inhibits granulocytic differentiation and promotes their self‑renewal. Le­ ukemia 2004; 18(7): 1238–1245. 27. https://ghr.nlm.nih.gov/gene/RARA [cit. 2021-02-18] 28. Nunes V S, Moretti N S. Nuclear subcompartments: an overview. Cell biology inter­ national 2016; 41: 2–7. 29. Wood A M, Garza‑Gongora AG, Kosak A. A crowdsourced nucleus : understanding nuclear organization in terms of dynamically networked protein function, BBA 2014; ISSN 1874-9399. 30. Lang M, Jegou T, Chung I, Three‑dimensional organization of promyelocytic leukemia nuclear bodies. J. Cell. Sci 2010; 123(3): 392–400. 31. Lausten‑Thomsen U, Madsen HO, Vestergaard TR et al. Prevalence of t(12;21)[ETV6-RUN­ X1]-positive cells in healthy neonates. Blood 2011; 117: 186–189. 32. Wayne AS, Baird K, Egeler RM. Hematopoietic stem cell transplantation for leukemia. Pediatr Clin North Am 2010; 57: 1–25. 33. Oliansky DM, Rizzo JD, Aplan PD. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence­ ‑based review. Biol Blood Marrow Transplant 2007; 13: 1–25. 34. Rosenthal J, Woolfrey AE, Pawlowska A et al. Hematopoietic cell transplantation with autologous cord blood in patients with severe aplastic anemia: an opportunity to revisit the controversy regarding cord blood banking for private use. Pediatr Blood Cancer 2011. 35. Ballen K K, Verter F, Kurtzberg J. Umbilical cord blood donation: public or private? Bone Marrow Transplant 2015; 50: 1271–1278. Rádi vám pomáháme v on-line vzdělávání Získejte také nové aktuální informace a kredity v rámci celoživotního vzdělávání ➜ https://online.solen.cz 23 on-line kurzů a kongresů 7200 účastníků 160 přednášek 1340 vydaných certi kátů